Spots Global Cancer Trial Database for recurrent colorectal carcinoma

Every month we try and update this database with for recurrent colorectal carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer	NCT06307548	Locally Advance... Recurrent Color... Stage III Color...	Aminolevulinic ... Biospecimen Col... Computed Tomogr... Fluorescence-Gu... Magnetic Resona... Photodynamic Th... Surgical Proced...	18 Years -	Roswell Park Cancer Institute
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma	NCT00545545	Recurrent Color... Progressive Col...	Safety and effi... Safety and effi...	18 Years - 75 Years	HiberCell, Inc.
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	NCT03095781	Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa...	XL888 Pembrolizumab	18 Years -	Emory University
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery	NCT02738606	Metastatic Colo... Metastatic Mali... Metastatic Mali... Recurrent Color... Resectable Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color...	Chemotherapy Laboratory Biom... Metastasectomy Quality-of-Life... Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Molecular Study and Precision Medicine for Colorectal Cancer	NCT05883683	Advanced Colore... Recurrent Color...	Molecular Profi...	18 Years - 75 Years	Wuhan Union Hospital, China
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery	NCT03087591	Metastatic Mali... Metastatic Soli... Recurrent Color... Recurrent Pancr... Recurrent Solid... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable So...	Laboratory Biom... siRNA-transfect...	18 Years -	Wake Forest University Health Sciences
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	NCT04017650	BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	M.D. Anderson Cancer Center
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer	NCT02508077	Recurrent Color... Stage IVA Color... Stage IVB Color...	Fluorouracil Irinotecan Hydr... Laboratory Biom... Leucovorin Calc... Panitumumab	18 Years -	City of Hope Medical Center
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	NCT04017650	BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	M.D. Anderson Cancer Center
Molecular Study and Precision Medicine for Colorectal Cancer	NCT05883683	Advanced Colore... Recurrent Color...	Molecular Profi...	18 Years - 75 Years	Wuhan Union Hospital, China
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	NCT03095781	Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa...	XL888 Pembrolizumab	18 Years -	Emory University
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia	NCT03823079	Recurrent Color... Thrombopenia	rhTPO irinotecan Raltitrexed radiotherapy rhIL-11	18 Years - 75 Years	Fudan University
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery	NCT02738606	Metastatic Colo... Metastatic Mali... Metastatic Mali... Recurrent Color... Resectable Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color...	Chemotherapy Laboratory Biom... Metastasectomy Quality-of-Life... Therapeutic Con...	18 Years -	M.D. Anderson Cancer Center
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	NCT04017650	BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	M.D. Anderson Cancer Center
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)	NCT05518032	Metastatic Micr... Recurrent Color... Stage III Color... Stage IV Colore... Unresectable Co...	Biopsy Pembrolizumab Therapeutic Aut...	18 Years -	Roswell Park Cancer Institute
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery	NCT02713373	Recurrent Color... Stage IVA Color... Stage IVB Color...	Cetuximab Laboratory Biom... Pembrolizumab	18 Years -	Roswell Park Cancer Institute
Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia	NCT03823079	Recurrent Color... Thrombopenia	rhTPO irinotecan Raltitrexed radiotherapy rhIL-11	18 Years - 75 Years	Fudan University
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	NCT03095781	Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa...	XL888 Pembrolizumab	18 Years -	Emory University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: